Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy

The identification of somatic activating mutations in JAK2(1–4) and in the thrombopoietin receptor (MPL)(5) in the majority of myeloproliferative neoplasm (MPN) patients led to the clinical development of JAK2 kinase inhibitors(6,7). JAK2 inhibitor therapy improves MPN-associated splenomegaly and sy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Koppikar, Priya, Bhagwat, Neha, Kilpivaara, Outi, Manshouri, Taghi, Adli, Mazhar, Hricik, Todd, Liu, Fan, Saunders, Lindsay M., Mullally, Ann, Abdel-Wahab, Omar, Leung, Laura, Weinstein, Abby, Marubayashi, Sachie, Goel, Aviva, Gönen, Mithat, Estrov, Zeev, Ebert, Benjamin L., Chiosis, Gabriela, Nimer, Stephen D., Bernstein, Bradley E., Verstovsek, Srdan, Levine, Ross L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3991463/
https://ncbi.nlm.nih.gov/pubmed/22820254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature11303
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados